Daily Morning Note – 29 November 2021


U.S. equity futures and crude oil rose Monday as traders weighed the possible impact of the omicron coronavirus strain on global economic reopening. Currency markets stabilized after Friday’s volatility.

Equity futures for Japan advanced, while Australian shares slid at the open and oil jumped back above $70 a barrel. The S&P 500 last week had its worst post-Thanksgiving performance since 1941 and the yield on 10-year Treasuries slid the most since March 2020.

The yen fell in early trading. The currency of South Africa, where the variant was identified, rose as much as 0.9% against the greenback. Bonds in Australia and New Zealand climbed.

Two South African health experts — including the doctor who first sounded the alarm about omicron — suggested the variant is presenting with mild symptoms so far. The World Health Organization urged caution, saying it will take time to assess the strain.



Jubilee Industries Holdings has entered a memorandum of understanding (MOU) to sell its fully-owned electronics unit, WE Components, for an indicative consideration of US$11 million, the Catalist-listed company said in a Saturday (Nov 27) bourse filing. The purchaser is Hangzhou Yu Ye Technology, a distributor of semiconductor products and solutions. The China-based company is set to acquire WE for US$4 million, as well as its inventory, which was valued at US$7 million as of end-September. The deal will expand Hangzhou Yu Ye’s overseas chip agency business through WE’s product portfolio. “The proposed disposal reflects the deep value of Jubilee’s electronics business unit that we have built over the years,” said the company’s executive chairman and chief, Terence Tea. Jubilee is 53.07 per cent-owned by Catalist-listed Accrelist, where Tea is also executive chairman and managing director.

Singapore-based virtual currency exchange Coinstore has begun operations in India at a time when the Indian government is preparing legislation to effectively bar most private cryptocurrencies. Coinstore has launched its web and app platform and plans for branches in Bangalore, New Delhi and Mumbai, which will act as its base in India for future expansion, its management said. “With nearly a quarter of our total active users coming from India, it made sense for us to expand into the market,” Mr Charles Tan, head of marketing at Coinstore told Reuters. Asked why Coinstore was launching India despite the pending clampdown on cryptocurrencies, Mr Tan said: “There have been policy flip-flops but we hope things are going to be positive and we are optimistic that the Indian government will come out with a healthy framework for cryptocurrencies.”


BioNTech said on Friday (Nov 26) it expects more data on a worrying new coronavirus variant detected in South Africa within 2 weeks to help determine whether its vaccine produced with partner Pfizer would have to be reworked. Pfizer and BioNTech said that if necessary they expect to be able to ship a new vaccine tailored to the emerging variant in approximately 100 days. “We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529,” BioNTech said in a statement when asked to comment. “We expect more data from the laboratory tests in 2 weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,” it added. Moderna said in a statement it is working to advance a booster candidate tailored to the new variant and has also been testing a higher dose of its existing booster and to study other booster candidates designed to protect against multiple variants. “A booster dose of an authorised vaccine represents the only currently available strategy for boosting waning immunity,” Moderna said in the statement.

An anti-Covid pill developed by Merck has proved effective in treating the disease, the US Food and Drug Administration (FDA) said Friday (Nov 26) in a much-awaited preliminary report. But the report, from an FDA advisory panel, cautioned that pregnant women should not use the drug, known as molnupiravir, saying the potential benefits do not outweigh the risks for those patients. The report is meant to provide guidance to an FDA experts panel convening Tuesday (Nov 30) to consider whether to authorise emergency use of molnupiravir. Approval, analysts say, would represent a major step forward in the battle against the global pandemic, handing healthcare professionals a powerful new tool to help those infected.

Oil prices plunged US$10 a barrel on Friday (Nov 26), their largest 1-day drop since April 2020, as a new variant of the coronavirus spooked investors and added to concerns that a supply surplus could swell in the first quarter. Oil fell with global equities markets on fears the variant, could dampen economic growth and fuel demand. The World Health Organization has designated the new variant, which it named Omicron, as “of concern,” according to the South African health minister. The United States, Canada, Britain, Guatemala and European countries are among those to restrict travel from southern Africa, where the variant was detected. Brent crude settled down US$9.50, or 11.6 per cent, to US$72.72 a barrel, a weekly decline of more than 8 per cent.

Gold steadied on Friday (Nov 26), taking a breather after an over 1 per cent rally sparked by a rush into safe-havens as concerns over a new coronavirus variant rattled risk appetite. Spot gold rose 0.2 per cent to US$1,791.97 per ounce by 6.49pm GMT, after going up as high as US$1,815.26. US gold futures settled 0.1 per cent higher at US$1,785.5. Authorities globally reacted with alarm to the virus variant, with the EU and Britain among those tightening border controls as researchers sought to establish out if the mutation was vaccine-resistant, triggering a selloff across markets that seeped into oil and other precious metals. But after the rally due to bullion’s safe-haven appeal, the overall bearish turn in commodities eventually claimed gold as well, said Jim Wyckoff, senior analyst at Kitco Metals, adding the market reaction was probably overblown.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR

iX Biopharma Ltd – Just a warm up

Recommendation: BUY (Maintained); TP: S$0.355

Last Done: S$0.23; Analyst: Paul Chew

– iX Biopharma signs outlicensing agreement for its Wafermine drug worth more than S$300mn (excluding royalties) with Nasdaq-listed Seelos Therapeutics. Seelos provides the regulatory, clinical development and local USA market knowledge to register and commercialise Wafermine and other ketamine-related products.

– Seelos will fund future development, manufacturing and commercialisation of Wafermine and related drugs. iX Biopharma will receive an upfront payment, development milestone, sales milestone and royalties.

– iX Biopharma retains the ownership over the WaferiX sublingual drug delivery technology. Wafermine is one of a portfolio of other drugs that iX Biopharma is re-purposing using Waferix. Our DCF (WACC 10%) TP is raised to S$0.355 (prev. S$0.335) as we incorporate a higher upfront fee of S$12.1mn and raise development income. Our BUY recommendation is maintained.

Thai Beverage PLC – Lockdown hangover continues

Recommendation: BUY (Upgraded); TP S$0.765, Last close: S$0.695; Analyst Paul Chew

– Results were below results expectations. FY21 revenue and PATMI were 90%/91% of our FY21e forecasts. 4Q21 EBITDA was down 34% YoY to Bt7.6bn.

= Spirit volumes declined 19% YoY in 4Q21. Weakness was due to promo sales a year ago and dampening consumer sentiment in Thailand.

– We lower FY22e EPS by 10% to 4.25 cents as we reduce PATMI on expectations of slower recovery in consumer spending. Forex assumptions have also been cut following the weakness in the Thai baht. We downgrade our recommendation from BUY to ACCUMULATE with a lower target price of S$0.765 (prev. S$0.86). Target price is based on 18x FY22e earnings, its 5-year average. The recovery post-lockdown is underway, but the pace may be slower than expected. Reopening of nightlife entertainment venues in Thailand will occur only in mid-January 2022. Consumer sentiment and income levels remain fragile after months of lockdown. ThaiBev has lifted the selling price of spirits to offset the higher material costs. Plans for beerco IPO are intact.

Technical Pulse: Merck & Co

Recommended: Technical BUY; Analyst: Chua Wei Ren

Merck & Co (US: MRK) Technical price action shows a bullish rebound despite a break below the diamond top pattern

Buy spot: 79.16 Stop loss: 75.00 Take profit 1: 90.00 Take profit 2: 96.41

POEMS Podcast: Let the Money Talk

Recent Podcasts:

Daily Morning Note – November 26, 2021

Daily Morning Note – November 25,2021

Daily Morning Note – November 24, 2021

Visit www.stocksbnb.com to learn more!

Join our Phillip Securities Research Telegram channel for the latest update on our stock coverage!

Click here to join: https://t.me/stocksbnb

Webinar Of The Week

Weekly Market Outlook: Keppel Corp, UMS Holdings, UG Healthcare, Hyphens Pharma, Q&M Dental Group…

Date: 22 November 2021

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com